Literature DB >> 12495094

Epidemiology and predictive values of risk factors for neonatal group B streptococcal sepsis.

G L Gilbert1, M C Hewitt, C M Turner, S R Leeder.   

Abstract

OBJECTIVES: To determine the incidence of and factors affecting risk factors for neonatal group B streptococcal (GBS) sepsis and their predictive values for intrapartum GBS carriage; to calculate the proportions of women eligible for intrapartum antibiotic prophylaxis (IAP) using different selection protocols.
DESIGN: Cohort study.
SETTING: Antenatal clinics and labour wards of a community hospital and a tertiary referral centre in western Sydney POPULATION: Women attending antenatal clinics during the study periods were invited to participate.
METHODS: Approximately 500 women attending antenatal clinics were screened for GBS carriage at 26-32 weeks gestation and at delivery, using several screening methods. Clinical risk factors for neonatal sepsis were recorded during labour. MAIN OUTCOME MEASURES: Incidence of antenatal anovaginal GBS carriage and clinical risk factors during labour, their predictive values for intra-partum GBS carriage and their relationship, if any, to demographic and obstetric factors.
RESULTS: Antenatal and intra-partum GBS carriage rates were similar but varied from 18% to 27%, depending on screening methods. The best positive and negative predictive values of antenatal GBS culture, for intra-partum carriage, were 69% (95% confidence interval (CI) 64-74) and 92% (95% CI 50-94) respectively Clinical risk factors occurred in similar proportions of GBS carriers and non-carriers.
CONCLUSIONS: Neither early antenatal screening nor clinical risk factors are reliable predictors of intra-partum GBS carriage. Intra-partum antibiotic prophylaxis based on GBS carriage or risk factors when carrier status is unknown would involve approximately 35% of women, compared with approximately 16% if based on risk factors only Both strategies would prevent similar proportions of neonatal deaths from GBS sepsis. Compliance with a preventive protocol is the most likely determinant of its overall effectiveness.

Entities:  

Mesh:

Year:  2002        PMID: 12495094     DOI: 10.1111/j.0004-8666.2002.00497.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  6 in total

1.  Antenatal screening for Group B Streptococcus: a diagnostic cohort study.

Authors:  Janet E Hiller; Helen M McDonald; Philip Darbyshire; Caroline A Crowther
Journal:  BMC Pregnancy Childbirth       Date:  2005-07-22       Impact factor: 3.007

2.  Group B streptococcal screening, intrapartum antibiotic prophylaxis, and neonatal early-onset infection rates in an Australian local health district: 2006-2016.

Authors:  Kathryn Braye; Maralyn Foureur; Koert de Waal; Mark Jones; Elise Putt; John Ferguson
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

3.  Group B streptococcal colonization: Prevalence and impact of smoking in women delivering term or near term neonates in a large tertiary care hospital in the southern United States.

Authors:  Philip Kum-Nji; Linda Meloy; John Pierce; Amanda Ritter; Rachel Wheeler
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

4.  Epidemiology, Antimicrobial Resistance, and Virulence Determinants of Group B Streptococcus in an Australian Setting.

Authors:  Sandra Jones; Peter Newton; Matthew Payne; Lucy Furfaro
Journal:  Front Microbiol       Date:  2022-06-14       Impact factor: 6.064

5.  Compliance with protocols for prevention of neonatal group B streptococcal sepsis: practicalities and limitations.

Authors:  Gwendolyn L Gilbert; Moira C Hewitt; Catherine M Turner; Stephen R Leeder
Journal:  Infect Dis Obstet Gynecol       Date:  2003

6.  Serotype-specific acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancy.

Authors:  Gaurav Kwatra; Peter V Adrian; Tinevimbo Shiri; Eckhart J Buchmann; Clare L Cutland; Shabir A Madhi
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.